TargED reports positive Phase 1 results for TGD001 at ASH 2025

TargED Biopharmaceuticals has announced positive results from a Phase 1 first-in-human study of its lead investigational thrombolytic fusion protein, TGD001, presented in an oral session at the American Society of Hematology (ASH) Annual Meeting 2025 in Orlando.

The Phase 1 clinical trial demonstrated that TGD001 was safe and well tolerated, with no spontaneous bleeding events observed across four ascending dose cohorts. These results support the continued clinical development of TGD001 as a next-generation targeted thrombolytic therapy.

Following these encouraging findings, TargED plans to initiate two Phase 1/2 clinical proof-of-concept studies evaluating TGD001 in patients with acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).

The upcoming studies aim to further assess the therapy’s safety, efficacy and potential to address significant unmet needs in thrombotic diseases.

Read the full press release here.